Latest Regulatory Approval News

Woodside Energy has raised its 2025 production guidance following a 1% increase in quarterly output, while progressing key projects like Scarborough and Beaumont New Ammonia on schedule. The company also secured long-term LNG supply deals and received critical regulatory approvals.

Evergreen Lithium has secured key regulatory approvals to begin reverse circulation drilling at its Mt Monger Gold Project, targeting high-potential gold prospects Duchess of York and Kiaki Soaks. The campaign aims to unlock valuable insights and guide further exploration in 2026.

Ballard Mining’s September quarter report highlights promising drilling results at its Mt Ida Gold Project and secures final approvals for a 2.0 Mtpa processing plant, underpinning its development ambitions.

Latrobe Magnesium Limited has announced a fully underwritten $10 million equity raise through a $6 million placement and a $4 million rights issue to fund its magnesium production expansion. The capital will support the commissioning of its Demonstration Plant and advance plans for a 10,000 tonne commercial facility.

Energy Transition Minerals has won court approval to acquire the Penouta tin-tantalum-niobium mine in Spain, marking a strategic expansion into Europe’s critical minerals sector.

Bass Oil Limited reported a 3% rise in September oil production, driven by a 20% uplift in Indonesian output, while awaiting regulatory approval for a strategic gas field acquisition.

Moho Resources has raised $2 million through a share placement to fund an extensive drilling and sampling campaign at its Bush Chook Project, aiming to validate historical gold anomalies and expand its resource base.

VHM Limited has obtained conditional financial backing of up to A$379 million from Export Finance Australia and the US Export-Import Bank to advance its Goschen Rare Earths and Mineral Sands Project in Victoria.

Freehill Mining reports strong magnetite concentrate grades at its Yerbas Buenas project, while advancing its aggregates business and exploring copper-gold opportunities in Chile.

PYC Therapeutics has kicked off a global Phase 1b repeat dose study of its investigational drug PYC-001 targeting Autosomal Dominant Optic Atrophy, a rare genetic eye disease with no current treatments. Initial dosing has begun, with key data expected in the second half of 2026.

Resouro Strategic Metals has raised CAD$1 million through the first tranche of a private placement, advancing its Tiros Titanium-Rare Earths Project in Brazil. The company plans to use the funds to progress engineering work ahead of a Preliminary Economic Assessment.

Nexsen Limited has initiated clinical trials for its StrepSure® GBS Rapid Sensor, a next-generation diagnostic device aimed at improving maternal health outcomes. The trial's success could pave the way for regulatory approval and early market penetration by the second half of 2026.